Literature DB >> 18522628

Does diabetes mellitus as a comorbid condition affect the health-related quality of life in prostate cancer survivors? Results of a population-based observational study.

Floortje Mols1, Annelies E Aquarius, Marie-Louise Essink-Bot, Neil K Aaronson, Paul J M Kil, Lonneke V van de Poll-Franse.   

Abstract

OBJECTIVE: To assess the health-related quality of life (HRQoL) of long-term, disease-free prostate cancer survivors and compare it with that of prostate cancer survivors with diabetes mellitus (DM), and a Dutch normative population, as comorbidity can have a major impact on HRQoL in cancer survivors. PATIENTS AND METHODS: The Eindhoven Cancer Registry was used to select all men diagnosed with prostate cancer from 1994 to 1998. Questionnaires on HRQoL (Short Form 36) and prostate specific problems (University of California, Los Angeles Expanded Prostate Cancer Index) were sent to 964 patients, and 780 (81%) responded. Excluding patients with disease progression, the sample comprised 525 with prostate cancer and 65 with both prostate cancer and DM. Survivors with DM were more likely to have other comorbid conditions at the time of survey besides DM than were those without DM (74% vs 60%, P = 0.05). At 5-10 years after diagnosis, patients with DM reported worse General Health Perceptions than patients without DM or the normative population (means 52, 61 and 63; P < 0.001). Patients with DM also reported worse Vitality scores (59 vs 63; P < 0.001) than the normative population. Regression analysis indicated that DM was negatively associated with General Health Perceptions (beta = -0.13; P < 0.01) and Vitality (beta = -0.12; P < 0.01). Survivors with DM did not report worse urinary and bowel function or bother, nor more sexual problems than those without DM.
CONCLUSIONS: Except for general health perceptions and vitality, the HRQoL of prostate cancer survivors with or without DM was comparable to a normative population. Survivorship selection can possibly explain, in part, why patients with DM did not report worse generic or disease-specific HRQoL than those without DM, as had been expected.

Entities:  

Mesh:

Year:  2008        PMID: 18522628     DOI: 10.1111/j.1464-410X.2008.07812.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  5 in total

1.  Diabetes mellitus and health-related quality of life in prostate cancer: 5-year results from the Prostate Cancer Outcomes Study.

Authors:  Melissa S Y Thong; Lonneke van de Poll-Franse; Richard M Hoffman; Peter C Albertsen; Ann S Hamilton; Janet L Stanford; David F Penson
Journal:  BJU Int       Date:  2010-11-11       Impact factor: 5.588

2.  The individual and combined effect of colorectal cancer and diabetes on health-related quality of life and sexual functioning: results from the PROFILES registry.

Authors:  Pauline A J Vissers; Melissa S Y Thong; Frans Pouwer; Brenda L den Oudsten; Grard A P Nieuwenhuijzen; Lonneke V van de Poll-Franse
Journal:  Support Care Cancer       Date:  2014-06-20       Impact factor: 3.603

3.  Breast and prostate cancer survivors in a diabetic cohort: results from the Living with Diabetes Study.

Authors:  Adedayo A Onitilo; Maria Donald; Rachel V Stankowski; Jessica M Engel; Gail Williams; Suhail A R Doi
Journal:  Clin Med Res       Date:  2013-05-13

Review 4.  The impact of having both cancer and diabetes on patient-reported outcomes: a systematic review and directions for future research.

Authors:  Pauline A J Vissers; Louise Falzon; Lonneke V van de Poll-Franse; Frans Pouwer; Melissa S Y Thong
Journal:  J Cancer Surviv       Date:  2015-10-01       Impact factor: 4.442

5.  Prospectively measured lifestyle factors and BMI explain differences in health-related quality of life between colorectal cancer patients with and without comorbid diabetes.

Authors:  Pauline A J Vissers; Melissa S Y Thong; Frans Pouwer; Geert-Jan Creemers; Gerrit D Slooter; Lonneke V van de Poll-Franse
Journal:  Support Care Cancer       Date:  2015-12-30       Impact factor: 3.603

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.